KYTX · Kyverna Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| GILEAD SCIENCES, INC. 10% Owner | ▲ Buy | Open Market | 4,126,119 Shares held | 2/12/2024 | View profile |
| Bain Capital Life Sciences Investors, LLC 10% Owner | ▲ Buy | Open Market | 3,163,868 Shares held | 2/12/2024 | View profile |
| Westlake BioPartners Opportunity Fund I, L.P. 10% Owner | ▲ Buy | Open Market | 869,317 Shares held | 12/18/2025 | View profile |
| Westlake BioPartners Fund I, L.P. 10% Owner | ▼ Sell | Other | 735,984 Shares held | 2/12/2024 | View profile |
| Northpond Ventures III GP, LLC | ▲ Buy | Open Market | 450,000 Shares held | 2/12/2024 | View profile |
| Christi Shaw Director | ▼ Sell | Tax Withholding | 66,741 Shares held | 5/27/2026 | View profile |
| Warner Weston Biddle Chief Executive Officer | ▲ Buy | Grant | 58,000 Shares held | 3/13/2026 | View profile |
| Ryan Alexander Jones Chief Financial Officer | ▲ Buy | Grant | 55,950 Shares held | 4/11/2025 | View profile |
| Karen Marie Walker Chief Technology Officer | ▼ Sell | Open Market | 22,636 Shares held | 12/15/2025 | View profile |
| Ian T. Clark Director | ▲ Buy | Grant | 21,727 Shares held | 5/27/2026 | View profile |
| Fred E. Cohen Director | ▲ Buy | Grant | 21,727 Shares held | 5/27/2026 | View profile |
| Beth C. Seidenberg Director | ▲ Buy | Grant | 21,727 Shares held | 5/27/2026 | View profile |
| Mert Aktar | ▲ Buy | Grant | 21,727 Shares held | 5/27/2026 | View profile |
| Naji Gehchan See Remarks | ▲ Buy | Grant | 18,000 Shares held | 3/13/2026 | View profile |
| Daniel K. Spiegelman Director | ▲ Buy | Grant | 16,634 Shares held | 5/29/2025 | View profile |
| Sravan Kumar Emany SVP, Chief Financial Officer | ▲ Buy | Grant | 11,006 Shares held | 2/24/2026 | View profile |
| Andrew Craig Miller | ▲ Buy | Grant | 11,006 Shares held | 2/24/2026 | View profile |
| Marc Grasso Chief Financial Officer | ▲ Buy | Grant | 10,000 Shares held | 3/13/2026 | View profile |
| Vida Ventures, LLC | ▲ Buy | Open Market | 583 Shares held | 2/12/2024 | View profile |
Transaction History
| Fred E. Cohen | ▲ Buy | Grant | 5,093 | $0 | 5/27/2026 |
| Beth C. Seidenberg | ▲ Buy | Grant | 5,093 | $0 | 5/27/2026 |
| Christi Shaw | ▼ Sell | Tax Withholding | 4,194 | $36K | 5/27/2026 |
| Mert Aktar | ▲ Buy | Grant | 5,093 | $0 | 5/27/2026 |
| Ian T. Clark | ▲ Buy | Grant | 5,093 | $0 | 5/27/2026 |
| Marc Grasso | ▲ Buy | Grant | 10,000 | $0 | 3/13/2026 |
| Warner Weston Biddle | ▲ Buy | Grant | 58,000 | $0 | 3/13/2026 |
| Naji Gehchan | ▲ Buy | Grant | 18,000 | $0 | 3/13/2026 |
| Sravan Kumar Emany | ▲ Buy | Grant | 11,006 | $0 | 2/24/2026 |
| Andrew Craig Miller | ▲ Buy | Grant | 11,006 | $0 | 2/24/2026 |
| Christi Shaw | ▲ Buy | Grant | 24,301 | $0 | 1/12/2026 |
| Christi Shaw | ▲ Buy | Grant | 30,000 | $0 | 1/12/2026 |
| Beth C. Seidenberg | ▲ Buy | Open Market | 133,333 | $1000K | 12/18/2025 |
| Westlake BioPartners Opportunity Fund I, L.P. | ▲ Buy | Open Market | 133,333 | $1000K | 12/18/2025 |
| Karen Marie Walker | ▲ Buy | Option Exercise | 23,998 | $116K | 12/15/2025 |
| Karen Marie Walker | ▼ Sell | Open Market | 23,998 | $293K | 12/15/2025 |
| Christi Shaw | ▲ Buy | Grant | 16,634 | $0 | 5/29/2025 |
| Beth C. Seidenberg | ▲ Buy | Grant | 16,634 | $0 | 5/29/2025 |
| Daniel K. Spiegelman | ▲ Buy | Grant | 16,634 | $0 | 5/29/2025 |
| Mert Aktar | ▲ Buy | Grant | 16,634 | $0 | 5/29/2025 |
| Ian T. Clark | ▲ Buy | Grant | 16,634 | $0 | 5/29/2025 |
| Fred E. Cohen | ▲ Buy | Grant | 16,634 | $0 | 5/29/2025 |
| Ryan Alexander Jones | ▲ Buy | Grant | 12,000 | $0 | 4/11/2025 |
| Karen Marie Walker | ▲ Buy | Grant | 13,000 | $0 | 4/11/2025 |
| Karen Marie Walker | ▲ Buy | Option Exercise | 9,636 | $43K | 6/6/2024 |
| Ryan Alexander Jones | ▲ Buy | Option Exercise | 10,870 | $8K | 5/28/2024 |
| Ryan Alexander Jones | ▲ Buy | Option Exercise | 7,146 | $5K | 5/28/2024 |
| Vida Ventures, LLC | ▼ Sell | Other | 4,523,924 | — | 2/12/2024 |
| Vida Ventures, LLC | ▲ Buy | Open Market | 252,553 | $5.6M | 2/12/2024 |
| Vida Ventures, LLC | ▲ Buy | Open Market | 583 | $13K | 2/12/2024 |
| Fred E. Cohen | ▼ Sell | Other | 4,523,924 | — | 2/12/2024 |
| Beth C. Seidenberg | ▼ Sell | Other | 3,787,940 | — | 2/12/2024 |
| Beth C. Seidenberg | ▼ Sell | Other | 735,984 | — | 2/12/2024 |
| Westlake BioPartners Fund I, L.P. | ▼ Sell | Other | 3,787,940 | — | 2/12/2024 |
| Westlake BioPartners Fund I, L.P. | ▼ Sell | Other | 735,984 | — | 2/12/2024 |
| Bain Capital Life Sciences Investors, LLC | ▼ Sell | Other | 2,713,868 | — | 2/12/2024 |
| Bain Capital Life Sciences Investors, LLC | ▲ Buy | Open Market | 450,000 | $9.9M | 2/12/2024 |
| GILEAD SCIENCES, INC. | ▼ Sell | Other | 3,216,119 | — | 2/12/2024 |
| GILEAD SCIENCES, INC. | ▲ Buy | Open Market | 910,000 | $20.0M | 2/12/2024 |
| Northpond Ventures III GP, LLC | ▲ Buy | Open Market | 450,000 | $9.9M | 2/12/2024 |
| Northpond Ventures III GP, LLC | ▼ Sell | Other | 2,805,426 | — | 2/12/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Kyverna Reports Positive One-Year Data for Miv-cel Trials
Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.
Kyverna Reports Positive One-Year Data for Miv-cel Trials. Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.